TopStockPlays.com brings you the most vibrant coverage of these BIIB, CTIC, CELG, AMGN
Pompano Beach, FL -- (SBWIRE) -- 01/14/2013 -- Biogen Idec Inc. (NASDAQ:BIIB) reported that it has submitted Biologics License Application (BLA) for the marketing approval to the U.S. Food and Drug Administration (FDA). It will be used for the treatment of hemophilia B.
Biogen Idec Inc. remained a bear for the day as itreported the loss of -0.08% and closed at $143.79 after gaining total volume of 1.79 million shares.
Can Investors Bet on BIIB after this News update? Find out in this Research Report
BIIB has the total of 236.60million outstanding shares and its total market capitalization is $34.02 billion.Company’s year to date performance remained quitepessimistic with the loss of -1.76% while in last 6 months it dropped almost -0.57%. During Last three months company reported a downward momentum of -2.32%.
Cell Therapeutics Inc (NASDAQ:CTIC) ended its day with the gaining stream with the gain of 4.11% and closed at the price of $1.52after opening at $1.49. Stock traded during its last trading session with the total traded volume of 2.52 million shares as compared to its average volume of 2.29 million shares.
During the previous session company’s minimum price was $1.46 while it touched its highest price for the day at $1.55. CTIC’s beta value stands at 5.36 points. During last one month company surged12.59% while its last 5 days shows arise of 17.83%.
Is CTIC a Solid Investment at These Levels? Read This Report For Details
Cell Therapeutics declared that company has introduced clinical trial sites and started began enrolling patients which is being evaluated for the treatment of patients with myelofibrosis, this is a Phase 3 clinical trial, known as PERSIST-1 or PAC325, for pacritinib, CTI's investigational JAK2 inhibitor.
Another biotech company has a positive moment for the day is Celgene Corporation (NASDAQ:CELG), it opened at the price of $95.78 whereas its previous closing price was recorded at $96.30. CELGgained 0.86% and traded within the day range of $94.45 - $96.33 for the day, 52week range of the stock remained in between $58.53 - $96.33. Total volume of the stock was 5.20 million shares during last trade while its average volume is 3.77 millionshares.
Company’s total market capitalization stands at $40.73 billion along with 422.99 million outstanding shares.
How Should Investors Trade CELG Now? Don’t Miss out a Special Trend Analysis
Amgen has a negative moment of the day Amgen, Inc. (NASDAQ:AMGN) reported the decrease of -0.97% to close at $86.96with the overall traded volume of 4.68 million shares. Its market capitalization was $66.73 billion. Its beta value stands at 0.40 times and earning per share was $5.59.
What AMGN’s Charts Are Signaling for Traders? Find Out Here
Amgen, Inc. (NASDAQ:AMGN) has the total of 767.36 million outstanding shares. During last trade company’s minimum price was $86.87 while it touched highest price of $88.05.
Company’s year to date performance remained quietoptimistic with the rise of 0.88%. If we look at last 6 months of trade that is in bullish zone with the surge of 12.99%.
The TopStockPlays.com expert team is highly experienced in picking the low-priced shares with the biggest profit potential. We uncover the hidden gems in the stock market-shares that can break out for gains of 300%, 400%, even 500% within a few weeks.
PLEASE NOTE WELL: The TopStockPlays.com employees are not registered as an Investment Adviser in any jurisdiction whatsoever. Please do your research or consults your financial adviser before making any Investment decision. TopStockPlays.com or its employees will not be responsible for any loss or losses.
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-321-1250 (International)